Besides, he is a professor of Oncology at the Roswell Park Cancer Institute in New York. As a young boy, Blagosklonny had an intense love for humanity and a vision of having a disease-free community on scimagojr.com, a factor that drove him into his career path. He earned his MD in Internal Medicine from the Medical University of St. Petersburg, and later got a Ph.D. in Experimental Medicine and Cardiology from the same university. In 2002, he was made the associate professor of medicine at the New York Medical College. Before joining the Roswell Park Cancer Institute in 2009, the distinguished professor on msubmit.net served as a senior scientist at Ordway Research Institute.
His Career at Roswell Park Cancer Institute
While at Roswell College, the professor on impactjournals.com has devoted most of his time in studying cancer including therapies to protect normal and healthy cells from getting damaged. Besides, he has interests in understanding the underlying mechanism of aging and anti- aging drugs. His vast experience and excellent achievements have made him become one of the most reputed and outstanding Oncology researchers.
His Editorial Activities
Blagosklonny is an author of more than 300 research articles, book chapters and reviews in Oncotarget and other publishing journal. His research on Oncotarget ranges from clinical investigations to cellular and molecular biology. He is also the founding editor and editor-in- chief of the cell cycle. Moreover, he is an Associate Editor of cancer biology and therapy,Oncotarget, PLOS ONE, American Journal of Pathology, Cell death, cancer research, International Journal of Cancer and Autophagy. In these articles, he has written about ontogenesis, tumor suppressors, apoptosis, anticancer therapeutics, mitosis, drug resistance for healthy cells, and signal transduction among many others.
About TOR Hypothesis
Blagosklonny developed a hypothesis regarding TOR (Target of Rapamycin) signaling potential role in Cancer and aging. He proposed the use of Rapamycin, which is a popular cancer drug to be a possible treatment for life extension. The professor is considered to be the most enthusiastic advocate for Rapamycin in longevity research for Oncotarget.